Recent statements from U.S. President Donald Trump regarding the reduction of prescription drug prices have led to significant shifts in financial markets. The decision, aimed at aligning U.S. drug prices with those in other countries, triggered a sharp response from stock markets in Europe and Asia. Pharmaceutical companies, in particular, saw substantial declines, which may have implications for their future.

Pharmaceutical stocks took a sharp hit on Monday following a renewed pledge by former U.S. President Donald Trump to slash prescription drug prices in the country. In a Truth Social post, Trump committed to reducing prices by 59% — a more aggressive figure compared to his earlier range of 30% to 80%, which he promised would take effect “almost immediately.”